Advertisement
Screener

NovoCure Limited (NVCR) Overview

NovoCure Limited (NVCR) Overview

  • 1 Apr 2026: Period ending 30 Jun 2026; Estimate (m); Actual -0.13; Beat / miss (m).
  • 1 Jan 2026: Period ending 31 Mar 2026; Estimate (m); Actual -0.62; Beat / miss (m).
  • 1 Jul 2025: Period ending 30 Sept 2025; Estimate (m); Actual -0.33; Beat / miss (m).
  • 1 Apr 2025: Period ending 30 Jun 2025; Estimate (m); Actual -0.36; Beat / miss (m).

Stock Price Chart

View more →

Blue: Split-adjusted close · Orange: Cumulative dividend-reinvested close

$9.53$11.16$13.07$15.30$17.92$20.992025-11-062026-11-06$9.53$15.94$26.66$44.59$74.58$124.752021-11-082026-11-06$5.79$12.17$25.56$53.69$112.77$236.862016-11-072026-11-06$5.65$11.93$25.18$53.16$112.21$236.862015-10-012026-11-06$5.65$11.93$25.18$53.16$112.21$236.862015-10-012026-11-06

Logarithmic scale. Both lines share the same starting value for the selected range.

Last close
$13.27
Previous close
$15.99
Change
-$2.72
Change (%)
-17.01%
Close date
2026-11-06
Previous close date
2026-09-29
Open
(m)
Day high
(m)
Day low
(m)
Last session volume
(m)
Last session value
(m)
Currency
USD
Price basis
split-adjusted
Volume basis
(m)

Performance

View more →

Cumulative total returns · 2026-09-29

YTD

NVCR
+23.67%
S&P 500
(m)

1 year

NVCR
+23.76%
S&P 500
(m)

3 years

NVCR
-0.99%
S&P 500
(m)

5 years

NVCR
-86.24%
S&P 500
(m)

Earnings trends

View more →

Earnings per share

USD / share · As filed

30 Jun 2026 ○ Estimate (m) ● Actual -0.13

-0.70-0.51-0.32-0.140.0531 Mar 2025: estimate (m); actual -0.3131 Mar 2025(m)30 Jun 2025: estimate (m); actual -0.3630 Jun 2025(m)30 Sept 2025: estimate (m); actual -0.3330 Sept 2025(m)31 Mar 2026: estimate (m); actual -0.6231 Mar 2026(m)30 Jun 2026: estimate (m); actual -0.1330 Jun 2026(m)
Comparison details
Period startPeriod endingEstimateActualBeat / missReport date
1 Apr 202630 Jun 2026(m)-0.13(m)(m)
1 Jan 202631 Mar 2026(m)-0.62(m)(m)
1 Jul 202530 Sept 2025(m)-0.33(m)(m)
1 Apr 202530 Jun 2025(m)-0.36(m)(m)
1 Jan 202531 Mar 2025(m)-0.31(m)(m)

31 Dec 2025 ○ Estimate (m) ● Actual -1.22

-2.03-1.62-1.21-0.79-0.3831 Dec 2021: estimate (m); actual -0.5631 Dec 2021(m)31 Dec 2022: estimate (m); actual -0.8831 Dec 2022(m)31 Dec 2023: estimate (m); actual -1.9531 Dec 2023(m)31 Dec 2024: estimate (m); actual -1.5631 Dec 2024(m)31 Dec 2025: estimate (m); actual -1.2231 Dec 2025(m)
Comparison details
Period startPeriod endingEstimateActualBeat / missReport date
1 Jan 202531 Dec 2025(m)-1.22(m)(m)
1 Jan 202431 Dec 2024(m)-1.56(m)(m)
1 Jan 202331 Dec 2023(m)-1.95(m)(m)
1 Jan 202231 Dec 2022(m)-0.88(m)(m)
1 Jan 202131 Dec 2021(m)-0.56(m)(m)

Revenue vs. Earnings

USD

30 Jun 2026 ■ Revenue 183.58M ■ Earnings -15.66M — Profit margin -8.53%

-101.70M-41.9%3.58M-30.4%108.87M-19.0%214.15M-7.5%30 Jun 2025: revenue 158.81M; earnings -40.14M; profit margin -25.28%30 Jun 202530 Sept 2025: revenue 167.20M; earnings -37.27M; profit margin -22.29%30 Sept 202531 Mar 2026: revenue 174.06M; earnings -71.14M; profit margin -40.87%31 Mar 202630 Jun 2026: revenue 183.58M; earnings -15.66M; profit margin -8.53%30 Jun 2026

31 Dec 2025 ■ Revenue 655.35M ■ Earnings -136.23M — Profit margin -20.79%

-310.48M-41.6%45.96M-33.2%402.40M-24.7%758.84M-16.3%31 Dec 2022: revenue 537.84M; earnings -93.00M; profit margin -17.29%31 Dec 202231 Dec 2023: revenue 509.34M; earnings -207.00M; profit margin -40.64%31 Dec 202331 Dec 2024: revenue 605.22M; earnings -169.00M; profit margin -27.92%31 Dec 202431 Dec 2025: revenue 655.35M; earnings -136.23M; profit margin -20.79%31 Dec 2025

Analyst insights

View more →
RatingsBuyHoldSellOther ratingsLast CloseAverage TargetUpsideHigh TargetLow Target
(m)(m)(m)(m)(m)$13.27(m)(m)(m)(m)
Past 12 Months12 Month ForecastLast Close$13.27High(m)Average(m)Low(m)2025-11-062026-11-06

Recent news

View more →

(m)

YouTube videos mentioning NVCR

View more →

(m)

Statistics

View more →

Retained observations as of 2026-11-11; financial period ending 30 Jun 2026.

Forward P/E
(m)
PEG ratio · 5-year expected
(m)
Shares held by insiders
(m)
Insider transactions · change (%)
(m)
Shares held by institutions
(m)
Institutional transactions · change (%)
(m)
Diluted EPS · 12 month
(m)
EPS estimate · next quarter
(m)
EPS estimate · next year
(m)
EPS growth · current annual estimate
(m)
EPS growth · next annual estimate
(m)
EPS growth · next 5 years expected
(m)
EPS growth · past 3 years annualized
(m)
EPS growth · past 5 years annualized
(m)
EPS change · 12 months vs prior year
(m)
EPS change · latest quarter vs previous quarter
(m)
Latest earnings report date
(m)
EPS surprise · latest reported quarter
(m)
Net income · 12 month
$-148.56M
Profit margin
-21.25%
Return on assets · 12 month
-14.56%
Named executive and board stock awards · latest fiscal year
(m)
Index membership
(m)
IPO date
(m)
Options available
(m)
Shortable
(m)
Analyst recommendation
(m)
Analyst target price
(m)
Price volatility · week
(m)
Price volatility · month
(m)
Average true range · 14 sessions
(m)
Relative strength index · 14 sessions
(m)
Relative volume
(m)
Average daily volume
1.05M
Latest session volume
(m)
Last session value
(m)
30 days ago session value
(m)
1 year ago session value
(m)
Number of trades
(m)
Total return · week
-3.96%*
Total return · month
-10.27%*
Total return · quarter
3.29%*
Total return · half year
45.76%*
Total return · year to date
23.67%*
Total return · 1 year
23.76%*
Total return · 3 years
-0.99%*
Total return · 5 years
-86.24%*
Market cap
(m)
Book value per share · latest quarter
(m)
Price / cash · latest quarter
(m)
Enterprise value
(m)
Enterprise value / revenue
(m)
Enterprise value / EBITDA
(m)
Dividend · 12 months per share
(m)
Dividend ex-date
(m)
Next dividend ex-date
(m)
Next dividend amount per share
(m)
Dividend growth · 3 years annualized
(m)
Dividend growth · 5 years annualized
(m)
Revenue · 12 month
$699.19M
Revenue growth · past 3 years annualized
(m)
Revenue growth · past 5 years annualized
(m)
Revenue change · 12 months vs prior year
(m)
Revenue change · latest quarter vs previous quarter
(m)
Revenue surprise · latest reported quarter
(m)
Levered free cash flow · 12 month
(m)
Debt / equity · latest quarter
(m)
Long-term debt / equity · latest quarter
(m)
Return on equity · 12 month
(m)
Return on invested capital · 12 months
(m)
Previous close
(m)
Latest closing price
(m)
Latest session change (%)
(m)
52-week high
(m)
52-week low
(m)
Price vs 20-session moving average
(m)
Price vs 50-session moving average
(m)
Price vs 200-session moving average
(m)
Float shares
(m)
Short float (%)
(m)
Short ratio (days to cover)
(m)
Short interest (shares)
(m)

Five-year projected P/E and P/S repeat the preceding five-year EPS and revenue CAGR, holding current price and market cap constant. Hover a calculated row for its formula. Net assets = assets − debt − payables − deferred revenue − obligations due within 1 year − obligations due after 1 year.

Holders breakdown

View more →
BreakdownOwnership
(m)Shares held by all insiders
(m)Shares held by institutions
(m)Float held by institutions
(m)Institutions holding shares

Other holders

(m)

View more →

Insider holders

(m)

View more →

Top institutional holders

(m)

View more →

Top mutual fund holders

(m)

View more →

NovoCure Limited Overview

View more →

(m)

(m)

SEC CIK
1645113
Industry (SIC)
3841 Surgical & Medical Instruments & Apparatus
Country of operation
Jersey
Business address
NO. 4 THE FORUM, GRENVILLE STREET, ST. HELIER, Jersey, Jersey
Fiscal year end
1231
Phone
44 (0)15 3475 6700

Similar stocks

Stock NameCountryMarket CapPE Ratio
LEMAITRE VASCULAR INC (LMAT)United States$1.848B33.37
Inspire Medical Systems, Inc. (INSP)United States$1.990B9.55
KESTRA MEDICAL TECHNOLOGIES, LTD. (KMTS)United States$1.535B-9.02
Alphatec Holdings, Inc. (ATEC)United States$1.531B-12.14
UFP TECHNOLOGIES INC (UFPT)United States$2.308B28.37
INTEGRA LIFESCIENCES HOLDINGS CORP (IART)United States$1.234B-193.02
ARTIVION, INC. (AORT)United States$1.123B-345.09
IRADIMED CORP (IRMD)United States$1.089B52.92
TANDEM DIABETES CARE INC (TNDM)United States$1.059B-16.57
PROCEPT BioRobotics Corp (PRCT)United States$1.001B-11.77